EMEA-003351-PIP01-22

EMEA-003344-PIP02-22

EMEA-003323-PIP01-22

Human medicines European public assessment report (EPAR): Xeplion, paliperidone, Date of authorisation: 04/03/2011, Revision: 17, Status: Authorised

Agenda of the CHMP meeting 22-25 July 2024

Draft guideline on the development and manufacture of oligonucleotides

Development and manufacture of oligonucleotides - Scientific guideline

Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0114/2023

Opinion/decision on a Paediatric investigation plan (PIP): Jyseleca, filgotinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0113/2023

Opinion/decision on a Paediatric investigation plan (PIP): Braftovi, Encorafenib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0148/2023